Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript Summary
Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript Summary
The following is a summary of the Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript:
以下是Kamada Ltd. (KMDA) Q2 2024業績會議調用摘要:
Financial Performance:
金融業績：
Kamada Ltd. reported a Q2 2024 revenue of $42.5 million, a 13% increase from Q2 2023.
Adjusted EBITDA for Q2 2024 was $9.1 million, a 51% increase compared to Q2 2023.
First half 2024 revenues reached $80.2 million, an 18% increase year-over-year, and adjusted EBITDA was $16.6 million, a 68% increase.
Gross profit for Q2 2024 was $19 million with a margin of 45%, compared to $14.4 million or 39% margin year-over-year.
Net income for Q2 2024 was $4.4 million, compared to $1.8 million in Q2 2023.
Kamada Ltd.報告2024年Q2營業收入4250萬美元，較2023年Q2增長13%。
2024年Q2調整後EBITDA爲910萬美元，較2023年Q2增長51%。
上半年2024年營業收入達到8020萬美元，同比增長18%，調整後EBITDA爲1660萬美元，同比增長68%。
2024年Q2毛利潤爲1900萬美元，毛利率爲45％，而去年同期爲1440萬美元，毛利率爲39％。
2024年Q2淨利潤爲440萬美元，而2023年Q2爲180萬美元。
Business Progress:
業務進展：
Launched first biosimilar product in Israel, planning another by year-end.
Expanding U.S. plasma collection operations with new centers in Beaumont, Houston, and San Antonio.
Ongoing pivotal Phase 3 clinical trial of inhaled AAT product.
在以色列推出第一個生物仿製藥物品，計劃在年底推出另一個。
在休斯敦，伯蒙特和聖安東尼奧設立新的血漿採集中心擴展美國血漿採集業務。
正在進行吸入型AAt產品的關鍵性3期臨床試驗。
Opportunities:
機會：
Anticipate increasing importance of biosimilars in distribution with potential annual sales between $30 million to $34 million.
Each new plasma collection center contributes $8 million to $10 million annual revenue.
Aiming for double-digit growth beyond 2024 supported by business development and M&A opportunities.
預計生物仿製藥在分銷中的重要性將增加，潛在年銷售額在3000萬美元至3400萬美元之間。
每個新的血漿採集中心爲年度收入貢獻800萬至1000萬美元。
通過業務拓展和併購機會，旨在實現2024年後的兩位數增長。
Risks:
風險：
Biosimilar product launches and clinical trials involve inherent risks, including regulatory and market acceptance challenges.
Plasma collection expansion and successful execution of M&A transactions are critical for sustained growth.
生物仿製藥物品的推出和臨床試驗都存在固有的風險，包括監管和市場接受挑戰。
血漿採集業務的擴展和併購交易的成功執行對於持續增長至關重要。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。